ELVN (Enliven Therapeutics) Other Operating Expense: $-0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELVN Enliven Therapeutics Inc ELVN
31 GF Score
Price $57.89
! 3 Warning Signs
View Full Analysis

What is Enliven Therapeutics Other Operating Expense?

Enliven Therapeutics ELVN -1.43% 31 Other Operating Expense is $-0.00 Mil as of Jun. 2026. GuruFocus rates ELVN with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Enliven Therapeutics's Other Operating Expense for the three months ended in Jun. 2026 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.00 Mil.

Enliven Therapeutics's quarterly Other Operating Expense increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil) and increased from Mar. 2026 ($-0.00 Mil) to Jun. 2026 ($0.00 Mil).

Enliven Therapeutics's annual Other Operating Expense declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then increased from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil).

Enliven Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Enliven Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enliven Therapeutics Other Operating Expense Chart

Enliven Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial 0.00 -0.00 0.00 -0.00 0.00

Enliven Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 -0.00 0.00
ELVN
31GF Score
Enliven Therapeutics Inc ELVN
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enliven Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.00 Mil mean?
Enliven Therapeutics (ELVN) has a Other Operating Expense of $-0.00 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Enliven Therapeutics and its competitors.
Is Enliven Therapeutics' Other Operating Expense too high?
Enliven Therapeutics' current Other Operating Expense is $-0.00 Mil. Overall, Enliven Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Enliven Therapeutics' Other Operating Expense compare to PBLS and CPRX?
Enliven Therapeutics' Other Operating Expense of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Enliven Therapeutics and its competitors. Enliven Therapeutics's current Other Operating Expense is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enliven Therapeutics stock overvalued right now?
Enliven Therapeutics (ELVN) has a current Other Operating Expense of $-0.00 Mil. The current Other Operating Expense is $-0.00 Mil. Enliven Therapeutics' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Enliven Therapeutics (ELVN), the current Other Operating Expense is $-0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enliven Therapeutics Business Description

Address 6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
31GF Score

Get the complete analysis for ELVN

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$57.89
Price